Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Adial Pharmaceuticals (ADIL) Profit After Tax (2022 - 2024)

Adial Pharmaceuticals' Profit After Tax history spans 3 years, with the latest figure at -$2.1 million for Q4 2024.

  • For Q4 2024, Profit After Tax fell 112.53% year-over-year to -$2.1 million; the TTM value through Dec 2024 reached -$13.2 million, down 215.93%, while the annual FY2025 figure was -$8.0 million, 39.56% up from the prior year.
  • Profit After Tax for Q4 2024 was -$2.1 million at Adial Pharmaceuticals, up from -$2.2 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $1.1 million in Q2 2023 and bottomed at -$6.5 million in Q1 2024.
  • The 3-year median for Profit After Tax is -$2.3 million (2024), against an average of -$2.3 million.
  • The largest annual shift saw Profit After Tax soared 128.27% in 2023 before it plummeted 325.99% in 2024.
  • A 3-year view of Profit After Tax shows it stood at -$931416.0 in 2022, then dropped by 4.61% to -$974373.0 in 2023, then tumbled by 112.53% to -$2.1 million in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Profit After Tax are -$2.1 million (Q4 2024), -$2.2 million (Q3 2024), and -$2.5 million (Q2 2024).